28
total announcements
GLAXO.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 20 Oct 2026
Market Cap
₹42,274 Cr
P/E (TTM)
39.6
P/E (Forward)
31.5
EPS (TTM)
₹63.05
52W Low
₹2,088.10
52W High
₹3,120.70
Dividend Yield
2.22%
Beta
0.07
Price / Book
18.6
Debt / Equity
1.5
Revenue (TTM)
₹3,955 Cr
Gross Margin
64.20%
Operating Margin
29.80%
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Reconciliation of Share Capital Audit' as required under Regulation 76 SEBI (Depositories and Participants) Regulations,2018.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing of new certificates on stock exchanges.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of its Q2 and H1 FY2026-27 financial results.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has submitted the Exchange a copy Scrutinizers report of Postal Ballot. The company has informed the Exchange regarding voting results.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has issued a corrigendum to its notice of postal ballot dated August 3, 2026, correcting a typographical error in the basic salary figure of Mr. Akshikar.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has issued a corrigendum to its postal ballot notice dated August 3, 2026, correcting a typographical error in the basic salary figure of Mr. Akshikar. The correction does not change the overall content of the notice, which was circulated to the company's members on August 13, 2026.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about a Corrigendum to the Notice of Postal Ballot dated August 3, 2026. The Corrigendum relates to a typographical error in the Explanatory Statement to the Notice. The error is in the Basicsalary figure of Mr. Akshikar, which should be read as Rs. 24,00,000/- per month instead of Rs. 24,00,0000/- per month. The Corrigendum forms an integral part of the Notice and must be read together with the Notice and the Explanatory Statement annexed thereto.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has received a tax refund of Rs 4.99 Crores for the assessment year 2025-2026.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about the completion of the dispatch of the Postal Ballot Notice to all the members for the appointment of a Non-Executive Director and the re-appointment of the Managing Director. The voting process will commence on 14th August 2026 and end on 13th September 2026.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Postal Ballot for appointment of Ms. Karine J F Natland as a Non-Executive Director & Re-appointment of Mr. Bhushan Akshikar as Managing Director.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about the transcript link uploaded on the website for the Q1 FY 2027 Earnings Call, where the management discussed the company's priorities, external performance, and growth in various therapy areas.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has received a refund of Rs 52.00 Cr from the ACIT Cir 7(1)(1) after a CIT-Appeal for the assessment year 1984-85.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has uploaded the recording of its analyst/institutional investor meeting on its website.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has published unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at ₹92.44 crore and net profit at ₹25.33 crore. The company has also appointed Mr. Ronak Shah as Associate Fund Manager - Fixed Income, effective August 3, 2026.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about the link of recording of Analysts/Institutional Investor Meet/Con. Call Updates.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about the resignation of a Director/KMP/SMP.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about change in Management, with Mr. Subesh Williams stepping down and Ms. Karine J F Natland being appointed as Non-Executive Director. Mr. Bhushan Akshikar is re-appointed as a Managing Director for a term of two years.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Change in Director(s) of the company. The company has announced the stepping down of Mr. Subesh Williams as Non-Executive Director and the appointment of Ms. Karine J F Natland as Non-Executive Director. Additionally, Mr. Bhushan Akshikar has been re-appointed as a Managing Director for a term of two years.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has announced the cessation of Subesh Wiliams as Non-Executive Director, appointment of Karine J F Natland as Non-Executive Director, and re-appointment of Bhushan Akshikar as Managing Director. The company has also released unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026.
GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited has announced its unaudited standalone and consolidated financial results for the first quarter ended 30th June 2026, along with the re-appointment of Mr. Bhushan Akshikar as Managing Director and the appointment of Ms. Karine J F Natland as Non-Executive Director.